International Cooperation
Beimei Pharmaceutical has licensed-in more than 10 products from Europe, the United States and Japan, including oral suspension, injection, and other formulations. Our products cover the entire pediatric population and provide a strong guarantee for the health of Chinese children.
In 2019, Beimei started to import and license-in products, including 5 FDA-approved pediatric drugs that year, including Oseltamivir Oral Suspension.
In 2023, Oselavir® (Oseltamivir Phosphate for Suspension), Presomid® (Esomeprazole Magnesium for Delayed-Release Oral Suspension) and Lancovul® (Lacosamide Oral Solution) imported by Beimei have been successfully won the bids in the 8th and 9th round of National Pharmaceutical VBP
In 2019, Beimei started to import and license-in products, including 5 FDA-approved pediatric drugs that year, including Oseltamivir Oral Suspension.
In 2023, Oselavir® (Oseltamivir Phosphate for Suspension), Presomid® (Esomeprazole Magnesium for Delayed-Release Oral Suspension) and Lancovul® (Lacosamide Oral Solution) imported by Beimei have been successfully won the bids in the 8th and 9th round of National Pharmaceutical VBP
